Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
27 November 2021

The Council of the University of the Free State (UFS) carefully considered and approved a vaccination policy for the institution during its meeting on 26 November 2021. 

The aim of the COVID-19 Regulations and Required Vaccination Policy is to regulate access of staff, ad hoc contract workers, and students to all the university’s premises. The policy will be implemented as from 14 February 2022.

“The policy implies that the university does not force anyone to be vaccinated, but the institution has the right to require vaccination if you want to access the institution’s premises in order to protect our staff and students,” said Prof Francis Petersen, UFS Rector and Vice-Chancellor.    

Fiduciary duty to ensure safe and caring environment

“The UFS is a residential university that requires face-to-face engagement by both staff and students, and operational requirements entail that our staff, ad hoc contract workers, and students are regularly exposed to large groups on the three campuses. We have a fiduciary duty to ensure a safe and caring environment and to meet the health and safety obligations on the campuses,” said Prof Petersen. 

Since March 2020 and within the national lockdown levels, the institution has followed a predominantly online emergency-remote learning-and-teaching programme with a minimalistic approach to the return of staff and students to campus. Where possible and within the national lockdown levels, staff members have been working from home, except essential service employees and academic staff that were required to support students studying on campus in carefully managed face-to-face classes/interactions.  

“The viability of consistent remote working and study conditions is not in line with the culture and strategy of the UFS. Although a blended learning approach is supported, sole online learning will be detrimental to the quality of our graduates and the experience that the institution should offer to its students as a residential university,” said Prof Petersen.

Encouraging university community to vaccinate

The institution is greatly concerned about the number of staff, students, and ad hoc contract workers who have tested positive for COVID-19 since the commencement of the national lockdown. The pandemic has resulted in numerous individuals being placed in quarantine, testing positive or being incapacitated due to COVID-19 complications and deaths. “We believe that the policy will be a contributing factor in encouraging the entire university community to make the responsible decision to vaccinate,” said Prof Petersen.

Although the policy does not force anyone to vaccinate, it is aimed at restricting campus access to vaccinated persons, while at the same time considering applications for exemption based on medical and religious grounds, natural immunity objections, other legally acceptable exemptions, or those participating in clinical trials approved by the South African Health Products Regulatory Authority (SAHPRA). Employee and Student Vaccination Exemption Committees will evaluate applications for exemption. These committees will operate independently, and will include medical, religious, legal and psychology experts.

Vaccinated persons will be required to upload their vaccination certificates on an electronic platform to obtain access to campus. Staff, ad hoc contract workers, and students who are not vaccinated, who do not have an approved exemption or deferral, and who do not have a SARS COVID-19 PCR negative result that is not older than a week, will not be allowed access to the campuses or facilities. Only vaccinated students will be allowed to access on-campus accommodation. 

Students who are not vaccinated by 14 February 2022, will not be prevented from registering for the academic year, but can only access the campus if vaccinated or granted an exemption. 

Consultation process and thorough risk assessment

“The development of the policy was consulted widely with relevant internal stakeholders, among others, the university’s Senate, supporting it with an overwhelming 84%. The university also followed due process by referring the proposed policy to all its governance structures for consultation – including obtaining opinions from reputable legal firms in the country,” said Prof Petersen. 

According to Prof Petersen, the UFS has conducted a thorough risk assessment of the implementation of the policy, and a contingency plan is in place that will be implemented in the absence of full implementation of the policy. “We will consider following a flexible approach if we initially find that the rate of vaccinations is low. We will work tirelessly with government to accelerate the rate of vaccinations with the ultimate goal to obtain a high enough level of vaccinations to limit the transmission of the COVID-19 virus and create a safe work and study environment for our staff and students,” he said. 

VIEW the Roads to Return to Campus 2022 Infographic here



Released by:
Lacea Loader (Director: Communication and Marketing)
Telephone: +27 51 401 2584 | +27 83 645 2454
Email: news@ufs.ac.za | loaderl@ufs.ac.za

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept